Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 27 Sep 2026 · Editorial standards

At a glance

NRG Oncology is the lead sponsor of 37 current clinical trials in our Canada, Mexico, Israel, Egypt, Japan, Ireland, South Korea, Australia, India, Switzerland, Norway, China, Taiwan and Singapore registers. 17 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Carboplatin, Paclitaxel and Apalutamide. The most-studied condition is Prostate Adenocarcinoma.

ClinicalTrials.gov trials by status

Recruiting1746%
Active, closed2054%

Trials by phase

Phase 32054%
Phase 2719%
Phase 2/3514%
Not applicable411%
Phase 113%

Clinical trials sponsored by NRG Oncology

37 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer NCT05946213 · ClinicalTrials.gov ↗ · Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8	Phase 3	Recruiting	2023-12	Switzerland, Canada, Mexico, Israel
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial NCT05327686 · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 Drugs: Avelumab, Axitinib, Cabozantinib	Phase 2	Recruiting	2023-02	Ireland, Canada, Australia, Israel
Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment NCT06279013 · ClinicalTrials.gov ↗ · Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm	Not applicable	Recruiting	2024-10	Mexico
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps NCT05080673 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum	Not applicable	Recruiting	2022-02	Mexico, Egypt
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer NCT06580314 · ClinicalTrials.gov ↗ · Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor Drugs: Bevacizumab, Olaparib	Phase 3	Recruiting	2025-03	Mexico, Japan
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer NCT04251052 · ClinicalTrials.gov ↗ · Ovarian Carcinoma	Not applicable	Recruiting	2020-09	Canada, Mexico, South Korea, Israel, Egypt
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) NCT04852887 · ClinicalTrials.gov ↗ · Stage I Breast Cancer	Phase 3	Recruiting	2021-06	Canada, Mexico, Japan
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery NCT03180268 · ClinicalTrials.gov ↗ · Grade 2 Meningioma, Intracranial Meningioma	Phase 3	Recruiting	2017-09	India, Canada, Mexico, Japan
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers NCT05408845 · ClinicalTrials.gov ↗ · Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Drugs: Docetaxel, Trastuzumab, Trastuzumab deruxtecan	Phase 2	Recruiting	2023-03	Mexico
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer NCT05624996 · ClinicalTrials.gov ↗ · Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8 Drugs: Abraxane, Carboplatin, CDDP	Phase 3	Recruiting	2023-07	Canada, Mexico
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer NCT06532279 · ClinicalTrials.gov ↗ · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Drugs: BMX-001, CDDP, Cisplatin	Phase 2	Recruiting	2025-06	Mexico
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 NCT05879926 · ClinicalTrials.gov ↗ · Breast Cancer Drug: Ovarian Function Suppression	Phase 3	Recruiting	2023-10	Canada, Mexico, Japan, Israel
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial NCT07166406 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8 Drugs: Atezolizumab, Bevacizumab, Durvalumab	Phase 3	Recruiting	2026-02	Canada, Mexico
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease NCT05174169 · ClinicalTrials.gov ↗ · Stage III Colon Cancer Drug: MFOLFIRINOX	Phase 2/3	Recruiting	2022-07	Canada, Mexico, Israel
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer NCT05646316 · ClinicalTrials.gov ↗ · Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 Drugs: IC-Green, Indocyanine Green	Phase 3	Recruiting	2022-12	South Korea
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer NCT04333537 · ClinicalTrials.gov ↗ · Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma	Phase 2/3	Recruiting	2020-09	Canada
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NCT06958328 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8 Drugs: 5-FU, Abraxane, Adrucil	Phase 3	Recruiting	2025-08	Canada
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study NCT05053152 · ClinicalTrials.gov ↗ · Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma Drug: Relugolix	Phase 2	Active, closed	2022-04	Canada, Mexico
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer NCT03137771 · ClinicalTrials.gov ↗ · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer Drugs: Docetaxel, Erlotinib, Gemcitabine	Phase 2	Active, closed	2017-04	Canada, Mexico, Israel
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery NCT04068103 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8 Drugs: 5-FU, Adrucil, Capecitabine	Phase 2/3	Active, closed	2019-12	Canada, Mexico
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04095364 · Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma Drugs: Carboplatin, Letrozole, Paclitaxel	Phase 3	Active, closed	2019-09	Ireland, Canada, Mexico, South Korea, Egypt
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial NCT03371719 · ClinicalTrials.gov ↗ · Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7 Drug: Apalutamide	Phase 2	Active, closed	2018-06	Norway, Canada, Mexico
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain NCT06500455 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma	Phase 3	Active, closed	2024-12	Ireland, Canada, Mexico, Israel
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial NCT04513717 · ClinicalTrials.gov ↗ · Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8 Drugs: Apalutamide, Bicalutamide, Buserelin	Phase 3	Active, closed	2021-01	Canada, Mexico, Israel
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer NCT03367702 · ClinicalTrials.gov ↗ · Stage II Prostate Adenocarcinoma AJCC v7	Phase 3	Active, closed	2018-02	Ireland, India, Switzerland, Canada, Mexico
Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial NCT06745024 · ClinicalTrials.gov ↗ · Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm	Phase 3	Active, closed	2025-05	Canada, Mexico
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA NCT02135042 · ClinicalTrials.gov ↗ · EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7 Drugs: Cisplatin, Fluorouracil, Gemcitabine	Phase 2/3	Active, closed	2014-07	China, Canada, Taiwan, Singapore, Australia
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases NCT05438212 · ClinicalTrials.gov ↗ · Metastatic Malignant Neoplasm in the Brain	Phase 3	Active, closed	2022-10	Canada, Japan, Israel
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial NCT05050084 · ClinicalTrials.gov ↗ · Prostate Adenocarcinoma Drugs: Bicalutamide, Buserelin, Darolutamide	Phase 3	Active, closed	2021-12	Canada, Mexico, Israel
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial NCT04134260 · ClinicalTrials.gov ↗ · Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8 Drug: Apalutamide	Phase 3	Active, closed	2020-04	Canada
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma NCT05095376 · ClinicalTrials.gov ↗ · Glioblastoma, Gliosarcoma Drugs: Lomustine, Temozolomide	Phase 3	Active, closed	2022-03	Canada, Mexico
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer NCT02488967 · ClinicalTrials.gov ↗ · Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative Drugs: Adriamycin, Carboplatin, Cyclophosphamide	Phase 3	Active, closed	2015-07	Norway, Canada, Israel, Egypt
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery NCT03070886 · ClinicalTrials.gov ↗ · Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7 Drugs: Bicalutamide, Degarelix, Docetaxel	Phase 2/3	Active, closed	2017-04	Canada, Israel
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol NCT03997370 · ClinicalTrials.gov ↗ · Malignant Solid Neoplasm Drugs: Carboplatin, Iohexol	Phase 1	Active, closed	2020-01	Israel
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors NCT05896189 · ClinicalTrials.gov ↗ · Breast Cancer, Cognitive Impairments	Not applicable	Active, closed	2024-02	Israel, Egypt
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability NCT04804644 · ClinicalTrials.gov ↗ · Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma	Phase 3	Active, closed	2021-06	Canada
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma NCT02179086 · ClinicalTrials.gov ↗ · Glioblastoma Drug: Temozolomide	Phase 2	Active, closed	2014-12	Canada

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in NRG Oncology trials

67 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 27 more in the trial list above.

Conditions in NRG Oncology trials

83 conditions

Prostate Adenocarcinoma5Stage III Prostate Cancer AJCC v83Stage II Prostate Adenocarcinoma AJCC v72Stage IVA Prostate Cancer AJCC v82Stage III Prostate Adenocarcinoma AJCC v72Metastatic Malignant Neoplasm in the Brain2Glioblastoma2 Breast Cancer2 Malignant Solid Neoplasm2Metastatic Renal Cell Carcinoma1Stage III Renal Cell Cancer AJCC v81Stage IV Renal Cell Cancer AJCC v81Unresectable Renal Cell Carcinoma1Low Grade Fallopian Tube Serous Adenocarcinoma1Ovarian Low Grade Serous Adenocarcinoma1Primary Peritoneal Low Grade Serous Adenocarcinoma1Stage II Fallopian Tube Cancer AJCC v81Anatomic Stage IV Breast Cancer AJCC v81Metastatic Breast Carcinoma1Metastatic Digestive System Carcinoma1Metastatic Lung Non-Small Cell Carcinoma1Grade 2 Meningioma1Intracranial Meningioma1EBV Infection1

By trial register

Register	Trials	Recruiting
Clinical trials in Canada	29	11
Clinical trials in Mexico	24	13
Clinical trials in Israel	14	5
Clinical trials in Egypt	5	2
Clinical trials in Japan	5	4
Clinical trials in Ireland	4	1
Clinical trials in South Korea	3	2
Clinical trials in Australia	2	1
Clinical trials in India	2	1
Clinical trials in Switzerland	2	1
Clinical trials in Norway	2	0
Clinical trials in China	1	0
Clinical trials in Taiwan	1	0
Clinical trials in Singapore	1	0

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Prostate Adenocarcinoma

Sponsor	Trials
Comprehensive Cancer Centre The Netherlands	1

Sponsors with the most current trials registered for this condition.

Questions about NRG Oncology trials

How many clinical trials does NRG Oncology sponsor?

NRG Oncology is the lead sponsor of 37 current trials on ClinicalTrials.gov in our Canada, Mexico, Israel, Egypt, Japan, Ireland, South Korea, Australia, India, Switzerland, Norway, China, Taiwan and Singapore registers, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are NRG Oncology trials recruiting?

Yes. 17 of its 37 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is NRG Oncology testing?

Its current trials name 67 drugs and biologicals as interventions. The most frequent are Carboplatin (4), Paclitaxel (4), Apalutamide (3), Bicalutamide (3) and Cisplatin (3). The number in brackets is how many of its trials name each drug.

Does NRG Oncology have clinical trials in Ireland?

Yes. 4 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

NRG Oncology clinical trials